Navigation Links
Endologix Announces First U.S. Implant of AFX™ Endovascular AAA System

IRVINE, Calif., Aug. 8, 2011 /PRNewswire/ -- Endologix, Inc. (Nasdaq: ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today that the first U.S. commercial implant of the Company's AFX™ Endovascular AAA System was performed at Edward Hines, Jr. VA Hospital in Chicago, IL. The procedure was performed by Ross Milner, M.D., F.A.C.S., Associate Professor and Chief of Vascular Surgery & Endovascular Therapy at Loyola University in Chicago, IL.

Dr. Milner commented, "We are excited to be the first hospital in the U.S. to bring the benefits of the new AFX system to a patient in our local community. The device builds on the compelling clinical evidence supporting Endologix's unique anatomical fixation technology with an enhanced, lower profile delivery system and new graft material. The 17Fr introducer sheath and integrated delivery system make it easy to use in a wide range of patient anatomies. The AFX system performed very well during the procedure; the delivery and deployment of the stent graft was quick and precise, and post-procedure imaging confirmed that the aneurysm was effectively sealed."

John McDermott, President and Chief Executive Officer of Endologix, commented, "We are pleased with the results from the initial implant and would like to thank Dr. Milner and his team for performing the procedure. We look forward to providing this exciting new endovascular device to physicians and patients in the U.S. in September."

About Endologix, Inc.Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's Web site at

Forward-Looking StatementsExcept for historical information contained herein, this news release contains forward-looking statements relating to the planned launch of the AFX system, the accuracy of which are necessarily subject to risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond the control of Endologix. Many factors may cause actual results to differ materially from anticipated results, including the uncertainties related to the introduction and clinical acceptance of new products. The Company undertakes no obligation to update its forward looking statements. Please refer to the Company's Annual Report on Form 10-K for the year ended December 31, 2010, and the Company's other filings with the Securities and Exchange Commission, for more detailed information regarding these risks and other factors that may cause actual results to differ materially from those expressed or implied.COMPANY CONTACT:


The Ruth GroupJohn McDermott, CEO

Nick Laudico (646) 536-7030(949) 595-7200

Zack Kubow (646)

SOURCE Endologix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Endologix to Present at Two Upcoming Conferences
2. Endologix Reports 22% Second Quarter 2011 Revenue Growth
3. Endologix and LeMaitre Vascular Enter Early Termination Agreement for European Distribution Rights of Endologix Products
4. Endologix to Report Second Quarter 2011 Financial Results on July 21, 2011
5. Endologix Announces FDA Approval of AFX™ Endovascular AAA System
6. Endologix to Present at the 2011 Bank of America Merrill Lynch Health Care Conference
7. Endologix Files Form 10-K; Nellix Purchase Price Allocation Finalized
8. Endologix to Present at the ROTH 23rd Annual OC Growth Stock Conference
9. Endologix Reports 41% Fourth Quarter 2010 Revenue Growth
10. Endologix Announces Presentation of Favorable Initial PEVAR Trial Results
11. Endologix Announces Favorable Clinical Results for Nellix Technology
Post Your Comments:
(Date:6/26/2016)... -- One of Australia,s successful biotechnology scientists, ... new biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). ... list on the ASX. Noxopharm is a clinic-ready company ... Phase 1 clinical study later this year. ... biggest problems facing cancer patients - the ability of cancers to ...
(Date:6/26/2016)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... Improvements Act of 1976, as amended ("HSR"), with respect ... Nasdaq: CPXX ) expired effective June 24, ... As previously announced on May 31, 2016, Jazz Pharmaceuticals ... which Jazz Pharmaceuticals has commenced a tender offer for ...
(Date:6/26/2016)...  VMS Rehab Systems, Inc. ( ) reported ... required to build a strong and stable market for ... on the OTC Markets-pink current trading platform. ... are seeing an anomaly in market trading activities that ... the Company, but shareholders and market players as well. ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... 2016 , ... The OSHA Training Center at Chabot-Las ... headquartered in Northern California, has issued an important reminder to employers to prevent ... Employers with workers exposed to high temperatures should establish a complete heat illness ...
(Date:6/27/2016)... Viejo, California (PRWEB) , ... June 27, 2016 , ... ... are fully customizable inside of Final Cut Pro X," said Christina Austin - CEO ... another unique style. Final Cut Pro X users can now reveal the ...
(Date:6/27/2016)... ... ... TherapySites, the leading website and online marketing ... Association. This new relationship allows TherapySites to continue to extend their online ... and promotional offers. , "TCA is extremely excited about this new partnership, as ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... patient payment industry today announced its strategic partnership with Connance, a healthcare ... , The two companies’ proven, proprietary technology combine to provide health systems, ...
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution ... the emergency ambulance transport experience for the millions of people who require these ... disrupted the taxi industry through the use of technology. Now, SmartEMS has put ...
Breaking Medicine News(10 mins):